PLX - Protalix BioTherapeutics, Inc.
| Previous Close | 0.433 |
| Open | 0.440 |
| Bid | 0.000 x 1100 |
| Ask | 0.000 x 800 |
| Day's Range | 0.433 - 0.450 |
| 52 Week Range | 0.380 - 0.920 |
| Volume | 66,489 |
| Avg. Volume | 423,631 |
| Market Cap | 65.375M |
| Beta | 2.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.261 |
| Earnings Date | Mar 10, 2016 - Mar 14, 2016 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.55 |
- ACCESSWIRE•21 days ago
Complimentary Technical Snapshots on Puma Biotech and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on PBYI sign up now at www.wallstequities.com/registration. The Company's shares have gained 8.95% in the last month, 10.72% over the last three months, and 18.26% over the past year.
- GlobeNewswire•last month
Report: Exploring Fundamental Drivers Behind Virtu Financial, Littelfuse, Gogo, Brookfield Asset Management, Protalix BioTherapeutics, and Halozyme Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, June 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Virtu ...
- GlobeNewswire•last month
Protalix BioTherapeutics Announces Additional Positive Results from Final Analysis of the Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis
Mucosal Improvement Observed in 61% of the Patients and 33% achieved Mucosal Healing. Clinical Responses Observed in 67% of the Patients and Clinical Remission Observed in 28% of the Patients. 89% of the ...
- ACCESSWIRE•2 months ago
Wired News - Protalix BioTherapeutics Presents Data About Fabry Disease Patients Screened in Phase-III BALANCE Study
LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Protalix BioTherapeutics, Inc. (NYSE: PLX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PLX as the Company's latest news hit the wire. On May 25, 2018, the Biopharmaceutical Company, which is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system ProCellEx, declared that it showcased data from the Phase-III BALANCE Study in a poster presentation at the 55th ERA-EDTA Congress (European Renal Association - European Dialysis and Transplant Association). Active-Investors.com is currently working on the research report for G1 Therapeutics, Inc. (NASDAQ: GTHX), which also belongs to the Healthcare sector as the Company Protalix BioTherapeutics.
- GlobeNewswire•2 months ago
Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress
GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that a poster presentation on the characteristics of Fabry disease patients screened in the phase III BALANCE clinical trial of pegunigalsidase alfa, a PEGylated alfa galactosidase alfa enzyme, or PRX-102, for the treatment of Fabry disease was presented at the 55th ERA-EDTA Congress (European Renal Association – European Dialysis and Transplant Association).
- GlobeNewswire•2 months ago
Protalix Announces Exchange and Discharge of Remaining 2018 Notes
Protalix BioTherapeutics, Inc. (the “Company”) (NYSE American:PLX) (PLX.TA) announced today that $3.42 million of the aggregate principal amount of the Company’s outstanding 4.5% Convertible Senior Notes due 2018 (the “Notes”) will be exchanged for 2,613,636 shares of the Company’s common stock and $2.27 million in cash. Additionally, the Company announced today that it has delivered the necessary funds under the indenture governing the Notes to effectively discharge the remaining outstanding Notes. Additional details regarding the exchange can be found in the Company’s Form 8-K to be filed with the Securities and Exchange Commission.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of PLX earnings conference call or presentation 9-May-18 12:30pm GMT
Q1 2018 Protalix Biotherapeutics Inc Earnings Call
- Associated Press•2 months ago
Protalix: 1Q Earnings Snapshot
The Carmiel, Israel-based company said it had a loss of 6 cents per share. The drug developer posted revenue of $4.6 million in the period. The company's shares closed at 40 cents. A year ago, they were ...
- GlobeNewswire•2 months ago
Protalix BioTherapeutics Reports 2018 First Quarter Results and Provides Corporate Update
CARMIEL, Israel, May 09, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary ...
- GlobeNewswire•3 months ago
Protalix BioTherapeutics to Hold First Quarter 2018 Financial Results and Corporate Update Conference Call on May 9, 2018
CARMIEL, Israel, April 26, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its ...
- ACCESSWIRE•4 months ago
Protalix BioTherapeutics, OPRX-106 Phase II Results, Analysts Review and Target, Catalysts
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
- Benzinga•4 months ago
Benzinga Pro's 5 Stock To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Athersys, Inc. (NASDAQ: ATHX ) stock gained more than ...
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of PLX earnings conference call or presentation 6-Mar-18 1:30pm GMT
Q4 2017 Protalix Biotherapeutics Inc Earnings Call
- Simply Wall St.•4 months ago
Protalix BioTherapeutics Inc (NYSEMKT:PLX): Are Analysts Optimistic?
Protalix BioTherapeutics Inc’s (AMEX:PLX): Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in IsraelRead More...
- ACCESSWIRE•4 months ago
Protalix Biotherapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 6, 2018 / Protalix Biotherapeutics, Inc. (NYSE American: PLX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 6, 2018, at 8:30 ...
- SmarterAnalyst•7 months ago
Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Fly 10% Following Impressive Phase II Interim Data in Ulcerative Colitis
Protalix Biotherapeutics Inc (NYSE:PLX) stock is riding a nearly 10% gain this morning after the Israeli biotech firm unleashed positive interim data from its Phase II clinical study in ulcerative colitis (UC). The trial is investigating the company's oral anti-TNF drug OPRX-106, with data set loose from the first 14 patients who have completed the randomized, open label, two-arm study. A total of 24 patients were enrolled and randomized to receive 2 mg or 8 mg of OPRX-106, administered orally, once daily, for 8 weeks. The first 14 patients have completed the study, and four patients are currently in treatment and follow-up. The trial evaluated key efficacy endpoints including clinical response and remission utilizing the Mayo score, as well as safety and pharmacokinetics.
